Acid-sensitive PEGylated cabazitaxel prodrugs for antitumor therapy

Liu, T (Liu, Tao)^{[ 1,2 ]} ; Zou, H (Zou, Hui)^{[ 1,2 ]} ; Mu, JQ (Mu, Jingqing)^{[ 1,2 ]} ; Yu, N (Yu, Na)^{[ 1,2 ]} ; Xu, Y (Xu, Yang)^{[ 1,2 ]} ; Liu, GH (Liu, Guohua)^{[ 1,2 ]} ; Liang, XJ (Liang, Xingjie)^{[ 3,4 ]} ; Guo, ST (Guo, Shutao)^{[ 1,2 ]}

CHINESE CHEMICAL LETTERS, 2021, 32(5): 1751-1754

DOI: 10.1016/j.cclet.2020.12.008

摘要

Although the antitumor drug cabazitaxel shows great therapeutic potential, its high toxicity and poor water solubility limit its utility. However, the use of stimuli-responsive prodrugs is a promising strategy for overcoming these limitations. Herein, we report the synthesis of two highly water soluble, acid sensitive PEGylated acyclic-ketal-linked cabazitaxel prodrugs (PKCs) with improved antitumor efficacy. In an acidic tumor microenvironment, the PKCs hydrolyzed rapidly to release the native drug, whereas they were stable in the normal physiological environment. Compared with cabazitaxel injection, the PKCs had much higher maximum tolerated doses; and in an MDA-MB-231 subcutaneous xenograft nude mouse model, the PKCs showed better antitumor efficacy and safety than cabazitaxel injection. The prodrug strategy reported herein could be useful for the development of other water soluble, acid sensitive prodrugs with improved efficacy.

(c) 2021 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.